Edition:
United Kingdom

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

15.90USD
16 Feb 2018
Change (% chg)

$-0.05 (-0.31%)
Prev Close
$15.95
Open
$16.00
Day's High
$16.30
Day's Low
$15.75
Volume
57,565
Avg. Vol
71,987
52-wk High
$17.35
52-wk Low
$6.35

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.12
Market Cap(Mil.): $302.10
Shares Outstanding(Mil.): 25.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Stemline Therapeutics Prices $51.8 Mln Public Offering

* STEMLINE THERAPEUTICS PRICES $51.8 MILLION PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Stemline Therapeutics Announces Proposed Public Offering Of Common Stock

* STEMLINE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

22 Jan 2018

BRIEF-Stemline Therapeutics reports Q3 loss per share $0.68

* Stemline Therapeutics reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​

* Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​

31 Oct 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,486 +18.00
Eisai Co., Ltd (4523.T) ¥5,575 +61.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,702 +2.00
Pfizer Inc. (PFE.N) $36.26 +0.55
Novartis AG (NOVN.S) CHF80.80 +1.18
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Roche Holding Ltd. (ROG.S) CHF225.50 +2.10
Roche Holding Ltd. (RO.S) CHF230.20 +2.60
Sanofi SA (SASY.PA) €64.50 +1.00
GlaxoSmithKline plc (GSK.L) 1,318.60 +18.20

Earnings vs. Estimates